Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026)
Cumberland Pharmaceuticals' (CPIX) quarterly Income from Non-Controlling Interests came in at $1947.0 in Q2 2026, down 64.81% year-over-year from $5533.0 in Q2 2025, and down 24.77% quarter-over-quarter from $2588.0 in Q1 2026.
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has disclosed Income from Non-Controlling Interests across 17 years of filings, most recently posting $1947.0 for Q2 2026.
- In Q2 2026, Income from Non-Controlling Interests fell 64.81% year-over-year to $1947.0; the TTM figure through Jun 2026 stood at -$20697.0 (down 448.55% YoY), while the FY2025 annual figure was -$28583.0, down 179.28% from the prior year.
- Income from Non-Controlling Interests came in at $1947.0 for Q2 2026 at Cumberland Pharmaceuticals, down from $2588.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $43791.0 in Q1 2024 to a low of -$29046.0 in Q2 2022.
- Average Income from Non-Controlling Interests over 5 years is -$6624.3, with a median of -$9465.0 recorded in 2023.
- Year-over-year, Income from Non-Controlling Interests surged 320.08% in 2024 and sank 878.59% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$18985.0 in 2022, then jumped by 60.07% to -$7581.0 in 2023, then jumped by 128.72% to $2177.0 in 2024, then slumped by 878.59% to -$16950.0 in 2025, then soared by 111.49% to $1947.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $1947.0 in Q2 2026, $2588.0 in Q1 2026, and -$16950.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 39.52 Mn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | - |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | 1,947.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,947.00 |
| Mar 31, 2026 | 2,588.00 |
| Dec 31, 2025 | -16,950.00 |
| Sep 30, 2025 | -8,282.00 |
| Jun 30, 2025 | 5,533.00 |
| Mar 31, 2025 | -8,884.00 |
| Dec 31, 2024 | 2,177.00 |
| Sep 30, 2024 | 7,112.00 |
| Jun 30, 2024 | -17,025.00 |
| Mar 31, 2024 | 43,791.00 |
| Dec 31, 2023 | -7,581.00 |
| Sep 30, 2023 | -13,921.00 |
| Jun 30, 2023 | -10,046.00 |
| Mar 31, 2023 | -19,898.00 |
| Dec 31, 2022 | -18,985.00 |
| Sep 30, 2022 | -14,587.00 |
| Jun 30, 2022 | -29,046.00 |
| Mar 31, 2022 | -17,180.00 |
| Dec 31, 2021 | -36,561.00 |
| Sep 30, 2021 | -31,415.00 |